ABSTRACT
The load of circulating tumor cells (CTC) is related to poor outcomes in cancer patients. A sufficient number of these cells would enable a full characterization of the cancer. An approach to probe larger blood volumes, allowing for the detection of more of these very rare CTC, is the use of leukapheresis. Currently available techniques allow only the analysis of a small portion of leukapheresis products. Here, we present a method that uses flow rather than static conditions which allows processing of larger volumes. We evaluated the conditions needed to isolate tumor cells from blood while passing antibody coated surfaces. Results show that our set-up efficiently captures cancer cells from whole blood. Results show that the optimal velocity at which cells are captured from blood is 0.6 mm s-1. Also, it can be concluded that the VU1D9 antibody targeting the EpCAM antigen has very high capture efficiency. When using an antibody that does not capture 100% of all cells, combining multiple antibodies on the capture surface is very beneficial leading to an increase in cell capture and is therefore worthwhile considering in any cancer cell capture methodology.
Subject(s)
Antibodies, Immobilized/immunology , Epithelial Cell Adhesion Molecule/immunology , Neoplastic Cells, Circulating/metabolism , Antibodies, Immobilized/chemistry , Cell Line, Tumor , Glass/chemistry , Humans , Lab-On-A-Chip Devices , Surface Properties , Time-Lapse ImagingABSTRACT
[This corrects the article DOI: 10.1039/C7RA09441H.].
